Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. cut its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 50.3% in the 1st quarter, HoldingsChannel.com reports. The fund owned 456,393 shares of the company’s stock after selling 461,714 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Zentalis Pharmaceuticals were worth $726,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ZNTL. Cerity Partners LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 58.7% during the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock valued at $33,000 after purchasing an additional 7,579 shares during the last quarter. Vident Advisory LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter worth about $45,000. Alpine Global Management LLC purchased a new stake in Zentalis Pharmaceuticals during the first quarter valued at about $48,000. CWM LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 725.3% in the first quarter. CWM LLC now owns 39,699 shares of the company’s stock worth $63,000 after buying an additional 34,889 shares during the period. Finally, 49 Wealth Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 70.9% in the first quarter. 49 Wealth Management LLC now owns 45,513 shares of the company’s stock worth $72,000 after buying an additional 18,874 shares during the period.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ZNTL. Wells Fargo & Company cut their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.84.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $1.50 on Wednesday. The stock’s 50-day moving average is $1.54 and its 200-day moving average is $1.45. The company has a market cap of $108.21 million, a P/E ratio of -0.66 and a beta of 1.76. Zentalis Pharmaceuticals, Inc. has a 52-week low of $1.01 and a 52-week high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.19. As a group, equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.